<i>Heyndrickxia coagulans</i> strain SANK70258 suppresses symptoms of upper respiratory tract infection via immune modulation: a randomized, double-blind, placebo-controlled, parallel-group, comparative study.

Front Immunol · 2024 · PMC11218553 · PMID 38957464

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

showed a trendp=0.05actually significant

Our hypothesis was also supported by the finding that CD304, one of the surface antigens of pDC, showed a trend towards higher gene expression levels after incubation in the HC group compared to the placebo group (p=0.05).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;i&gt;Heyndrickxia coagulans&lt;/i&gt; strain SANK70258 suppresses symptoms of upper respiratory tract infection via immune modulation: a randomized, double-blind, placebo-controlled, parallel-group, comparative study.

The sentences

<i>Heyndrickxia coagulans</i> strain SANK70258 suppresses symptoms of upper respiratory tract infection via immune modulation: a randomized, double-blind, placebo-controlled, parallel-group, comparative study.